Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. [electronic resource]
Producer: 20201023Description: 97-106 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Agents, Immunological -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- B7-H1 Antigen -- analysis
- Drug Combinations
- Esophageal Neoplasms -- drug therapy
- Esophagogastric Junction -- immunology
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Oxaliplatin -- administration & dosage
- Oxonic Acid -- administration & dosage
- Progression-Free Survival
- Receptor, ErbB-2 -- analysis
- Remission Induction -- methods
- Stomach Neoplasms -- drug therapy
- Tegafur -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.